Mitchell Elkind, MD

Dr. Mitchell S. V. Elkind gained his medical degree in 1992 from Harvard Medical School, and subsequently trained in Internal Medicine at Brigham and Women’s Hospital and in Neurology at Massachusetts General Hospital, both in Boston. He holds a Masters degree in Epidemiology from Columbia University. Currently, Dr. Elkind is a tenured Associate Professor of Neurology and Epidemiology in the Stroke Division at Columbia University, the Fellowships Director for the Neurology Department, and past Neurology Residency Program Director. He is also the Editor of the Neurology Resident and Fellow Section, a section of the journal devoted to education and mentoring of trainees. His research is focused on inflammatory and infectious biomarkers in stroke risk prediction, as well as acute stroke therapy. Dr. Elkind is the Principal Investigator of 3 independent investigator awards from NIH/NINDS. He is a Co-PI of the Northern Manhattan Study (NOMAS), an epidemiological study of stroke risk factors, and the principal investigator of NeuSTART (Neuroprotection with Statin Therapy for Acute Recovery Trial), a clinical trial evaluating short-term high-dose statin therapy in acute stroke. He is also the PI of the Levels of Inflammatory Markers in Treatment of Stroke (LIMITS) study, a multicenter study evaluating the role of inflammatory biomarkers in stroke prognosis, and a co-investigator and laboratory director for the Vasculopathy and Infection in Pediatric Stroke Study (VIPS). He is a fellow of the American Academy of Neurology and the Stroke Council of the American Heart Association, as well as a member of the American Neurological Association.

  • Find Columbia Doctors